• THERAPEUTIC INDICATIONS

This medicine is indicated for:

Carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following:  

• Brain tumours – glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumours. 
• Multiple myeloma – in combination with glucocorticoid such as prednisone. 
• Hodgkin’s disease – as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 
• Non-Hodgkin’s lymphomas – as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 
• Conditioning treatment prior to autologous hematopoietic stem cell transplantation (SCT) in malignant haematological diseases (Hodgkin/Non-Hodgkin lymphoma)